Global Drug-Device Combination Products Market Growth (Status and Outlook) 2023-2029

Global Drug-Device Combination Products Market Growth (Status and Outlook) 2023-2029

Combination products are therapeutic and diagnostic products that combine drugs, devices and/or biological products, leading to safer and more effective treatments thanks to careful and precise drug targeting, local administration and individualized therapy. These technologies can especially benefit patients suffering from serious diseases and conditions such as cancer, heart disease, multiple sclerosis and diabetes, among others. On the other hand, drug-device combination products have also introduced a new dynamic in medical product development, regulatory approval and corporate interaction.

LPI (LP Information)' newest research report, the “Drug-Device Combination Products Industry Forecast” looks at past sales and reviews total world Drug-Device Combination Products sales in 2022, providing a comprehensive analysis by region and market sector of projected Drug-Device Combination Products sales for 2023 through 2029. With Drug-Device Combination Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug-Device Combination Products industry.

This Insight Report provides a comprehensive analysis of the global Drug-Device Combination Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drug-Device Combination Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drug-Device Combination Products market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug-Device Combination Products and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug-Device Combination Products.

The global Drug-Device Combination Products market size is projected to grow from US$ 34430 million in 2022 to US$ 53420 million in 2029; it is expected to grow at a CAGR of 6.5% from 2023 to 2029.

Global key drug-device combination products players include GSK, Novo Nordisk and Eli Lilly etc. The top 3 companies hold a share about 32%. North America is the largset market with a share about 42%, followed by Europe and Asia-Pacific.

In terms of product, nebulizer & inhaler is the largest segment with a share about 36%. And in terms of applications, the largset application is hospital and clinic with a share about 47%.

This report presents a comprehensive overview, market shares, and growth opportunities of Drug-Device Combination Products market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Drug-Coated Device
Prefilled Drug Delivery Systems
Nebulizer and Inhaler
Transdermal Delivery System
Others

Segmentation by application
Hospital andClinic
Retail Pharmacies
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GSK
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
Boston Scientific
Abbott
Boehringer Ingelheim
Medtronic
Mylan
3M
Hisamitsu
Smith & Nephew
Molnlycke
Teleflex
BD
Lepu Medical
MicroPort
Terumo
B. Braun
Antares Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.